Celgene (CELG) Updates FY 2018 Earnings Guidance

Share on StockTwits

Celgene (NASDAQ:CELG) issued an update on its FY 2018 earnings guidance on Monday morning. The company provided earnings per share guidance of $8.75-8.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.79. The company issued revenue guidance of $15.2-15.2 billion, compared to the consensus revenue estimate of $15.23 billion.Celgene also updated its FY 2019 guidance to $10.60-10.80 EPS.

Shares of NASDAQ CELG opened at $84.90 on Monday. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99. The stock has a market capitalization of $59.37 billion, a price-to-earnings ratio of 12.41, a price-to-earnings-growth ratio of 0.43 and a beta of 1.44. Celgene has a fifty-two week low of $58.59 and a fifty-two week high of $107.29.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.02 by $0.27. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. On average, equities analysts anticipate that Celgene will post 7.45 earnings per share for the current year.

A number of equities research analysts recently commented on the company. BidaskClub downgraded Celgene from a buy rating to a hold rating in a report on Thursday, September 13th. UBS Group set a $94.00 target price on Celgene and gave the stock a buy rating in a report on Saturday, October 27th. Wells Fargo & Co decreased their target price on Celgene from $90.00 to $84.00 and set a market perform rating for the company in a report on Thursday. ValuEngine raised Celgene from a strong sell rating to a sell rating in a report on Friday. Finally, Morgan Stanley decreased their target price on Celgene from $93.00 to $88.00 and set an equal weight rating for the company in a report on Wednesday, December 19th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $113.87.

COPYRIGHT VIOLATION NOTICE: This article was published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/4062608/celgene-celg-updates-fy-2018-earnings-guidance.html.

About Celgene

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Read More: Liquidity

Earnings History and Estimates for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Henry Schein, Inc.  Expected to Announce Earnings of $1.11 Per Share
Henry Schein, Inc. Expected to Announce Earnings of $1.11 Per Share
Brokerages Expect Nike Inc  to Announce $0.63 Earnings Per Share
Brokerages Expect Nike Inc to Announce $0.63 Earnings Per Share
Raymond James Upgrades Commerce Bancshares  to “Market Perform”
Raymond James Upgrades Commerce Bancshares to “Market Perform”
Brokerages Expect Nike Inc  to Announce $0.63 Earnings Per Share
Brokerages Expect Nike Inc to Announce $0.63 Earnings Per Share
Zacks Investment Research Lowers Orange  to Sell
Zacks Investment Research Lowers Orange to Sell
Earthstone Energy’s  “Outperform” Rating Reaffirmed at Imperial Capital
Earthstone Energy’s “Outperform” Rating Reaffirmed at Imperial Capital


Leave a Reply

© 2006-2019 Ticker Report